Dorothee von Laer and her team are investigating heterologous SARS-CoV-2 vaccination with AstraZeneca (Vaxzevria) and BioNTech (Comirnaty). The trial was started in May 2021 and is planned to be completed by the end of the year. The main goal is to analyze the safety and efficacy of the heterologous vaccination with Vaxzevria followed by Comirnaty. Participants are enrolled in three study arms with 1000 individuals each (aged 18-65) and receive either 2x Comirnaty 3-7 weeks apart, 2x Vaxzevria 12 weeks apart, or Vaxzevria followed by Comirnaty 12 weeks apart. Primary outcome measures are neutralizing antibodies, T cell response and vaccine failures.
During this webinar, Dorothee von Laer will present first data and results. Dorothee von Laer is a German physician and virologist and has been a professor at the department of virology at the Medical University of Innsbruck since 2010.
VACCELERATE, the EU funded clinical research network for the coordination & conduct of COVID-19 vaccine trials is looking forward to host this webinar. Prof. Dorothee von Laer will present the study, goals and give insights into first results.